| Species |
Mouse |
| Protein Construction |
PLA2G7 (Phe22-Asn440)_x000D_
Accession # Q60963 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
47.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Endogenous PLA2G7 transcription levels were found to be significantly lower in vascular related cell lines than in the other cell lines. Luciferase reporter gene assays indicated that gene activity was significantly enhanced by PLA2G7 promoter fragment. LA2G7 transcription was found to be up-regulated with the treatment of DAC. The 17-β-estradiol was found to down-regulate PLA2G7 transcription in all the cell lines. |
| Synonyms |
LDL-PLA2; PAFAD; PAFAH |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
